Proteros Enters into New Research Collaboration with Johnson & Johnson Innovation on Sub-Class of Epigenetic Targets
July 27 2017 - 4:16AM
Business Wire
Proteros biostructures GmbH announced today that the company has
entered into a collaboration with Janssen Biotech, Inc., one of the
Janssen Pharmaceutical Companies of Johnson & Johnson, on a
sub-class of epigenetic targets. The deal was facilitated by
Johnson & Johnson Innovation.
The new collaboration agreement is focused on the discovery of
novel lead compounds against several epigenetic targets for various
cancer indications. Under the agreement, Janssen gains access to
Proteros' proprietary Nucleosomal Epigenetic Assay Technology
(NEATTM) and discovery platform aimed at technically complex
targets to identify quality lead compounds. Janssen has the option
to license the lead compounds for further development and
commercialization or the parties may jointly further develop and
partner.
Financial terms of the collaboration were not disclosed.
Dr. Torsten Neuefeind, CEO of Proteros commented: "We are
pleased to be working with Janssen to address a set of novel and
complex epigenetic targets to create oncology drugs. We believe
that the structure of the collaboration will accelerate the
discovery of novel therapies and maximize the value generation for
both parties."
About Proteros biostructures
Proteros, Martinsried/Munich, is a Germany-based, private
biotech company aimed at drug discovery for novel and technically
demanding targets, and co-founded by Nobel-prize winner Robert
Huber, a pioneer in structural biology. The company is today
working for most of the largest pharmaceutical and biotech
companies in collaborative relationships and has built a pipeline
of partnered and proprietary discovery projects with a particular
focus in epigenetics. Proteros has a strong platform for the
discovery of small molecules for technically demanding targets
which is pivotal for addressing the often complex nature of
epigenetic targets. A key element are the Nucleosomal Epigenetic
Assay Technologies (NEAT) which provide access to assay and
screening approaches with the most pharmacologically relevant
substrates, thus opening novel gateways to these types of relevant
targets. More information can be found at www.proteros.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170727005544/en/
Proteros Contacts:Dr. Torsten Neuefeind, CEOProteros
biostructures GmbHEmail: neuefeind@proteros.deorFor Press
Enquiries:CEO Raimund Gabriel, Dr. Cora KaiserMC Services
AGcora.kaiser@mc-services.eu